Scarica l'app Stockscreener
12.93
2.54%
0.32
Dopo l'orario di chiusura:
12.90
-0.03
-0.23%
Precedente Chiudi:
$12.61
Aprire:
$12.73
Volume 24 ore:
2.46M
Relative Volume:
1.14
Capitalizzazione di mercato:
$965.21M
Reddito:
$65,400
Utile/perdita netta:
$-46.34M
Rapporto P/E:
-14.05
EPS:
-0.92
Flusso di cassa netto:
$-38.74M
1 W Prestazione:
+25.17%
1M Prestazione:
+13.72%
6M Prestazione:
+23.38%
1 anno Prestazione:
+169.66%
Intervallo 1D:
$12.50
$12.97
Intervallo di 1 settimana:
$9.935
$12.97
Portata 52W:
$4.67
$17.43
CorMedix Inc Stock (CRMD) Company Profile
Nome
CorMedix Inc
Settore
Industria
Telefono
908-517-9500
Indirizzo
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
Confronta CRMD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRMD
CorMedix Inc
|
12.93 | 941.32M | 65,400 | -46.34M | -38.74M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-30 | Downgrade | D. Boral Capital | Buy → Hold |
| 2025-06-30 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-07 | Iniziato | Leerink Partners | Outperform |
| 2025-01-13 | Iniziato | D. Boral Capital | Buy |
| 2024-08-26 | Iniziato | Rodman & Renshaw | Buy |
| 2023-08-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-02-17 | Iniziato | Needham | Buy |
| 2020-09-29 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-09-21 | Iniziato | Truist | Buy |
| 2019-12-18 | Iniziato | B. Riley FBR | Buy |
| 2019-03-26 | Reiterato | H.C. Wainwright | Buy |
| 2018-12-06 | Iniziato | ROTH Capital | Buy |
| 2017-09-25 | Reiterato | H.C. Wainwright | Buy |
| 2017-08-10 | Reiterato | Rodman & Renshaw | Buy |
| 2017-05-05 | Reiterato | Rodman & Renshaw | Buy |
| 2016-11-11 | Reiterato | FBR & Co. | Outperform |
| 2016-03-17 | Reiterato | FBR Capital | Outperform |
| 2016-03-03 | Iniziato | FBR Capital | Outperform |
| 2015-11-16 | Reiterato | ROTH Capital | Neutral |
| 2015-10-29 | Reiterato | ROTH Capital | Neutral |
| 2015-05-06 | Downgrade | ROTH Capital | Buy → Neutral |
| 2014-12-08 | Reiterato | ROTH Capital | Buy |
| 2011-10-03 | Downgrade | Maxim Group | Buy → Hold |
Mostra tutto
CorMedix Inc Borsa (CRMD) Ultime notizie
Needham Maintains a Buy Rating on CorMedix (CRMD) With a $20 PT - MSN
CorMedix Inc. Advances in Infection Prevention with DEFENCATH® Study - TipRanks
Why CorMedix (CRMD) Might be Well Poised for a Surge - sharewise.com
Cormedix Inc. Advances Pediatric Study on DefenCath® for Infection Prevention - TipRanks
Statutory Earnings May Not Be The Best Way To Understand CorMedix's (NASDAQ:CRMD) True Position - simplywall.st
CorMedix (CRMD.O) Surges 8% — Is It a Technical Trigger or a Broader Sector Play? - AInvest
CorMedix Raises $150M in Convertible Notes Offering - AInvest
Time to Buy Eli Lilly and Other Undervalued Healthcare Stocks? - ca.finance.yahoo.com
Will CorMedix Inc. benefit from AI trendsJuly 2025 Chart Watch & Daily Technical Forecast Reports - mustnews.co.kr
Momentum Screeners Rank CorMedix Inc. in Top 5 TodayAI Screening for Swing Trade Picks Finds Momentum - 선데이타임즈
CorMedix Inc. Just Beat EPS By 50%: Here's What Analysts Think Will Happen Next - 富途牛牛
CorMedix Completes $150M Convertible Notes Offering - TipRanks
CorMedix completes $150 million convertible notes offering on Nasdaq By Investing.com - Investing.com Nigeria
CorMedix completes $150 million convertible notes offering on Nasdaq - Investing.com
Unpacking CorMedix’s 14.2% Intraday Surge: What’s Driving the Move? - AInvest
CorMedix (CRMD.O) Surges 9.7% Intraday—No Fundamentals, So What's Driving It? - AInvest
CorMedix’s SWOT analysis: acquisition boosts biopharmaceutical stock’s outlook - Investing.com
Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus - Zacks Investment Research
CorMedix Inc. (NASDAQ:CRMD) Q2 2025 Earnings Call Transcript - Insider Monkey
CorMedix Inc. Earnings Call Highlights Strategic Growth - TipRanks
Both Individual Investors Who Control a Good Portion of CorMedix Inc. (NASDAQ:CRMD) Along With Institutions Must Be Dismayed After Last Week's 16% Decrease - 富途牛牛
CorMedix Inc. stock trend outlook and recovery pathShort Squeeze Opportunities with Indicators - Newser
Is CorMedix Inc. part of any ETFShort-Term Gainers List - thegnnews.com
CorMedix Inc. stock trend forecastFree Real-Time Analysis With Entry Targets - Newser
Strategic Value and Growth Potential of CorMedix Post-Melinta Acquisition - AInvest
CorMedix Strikes $300M Deal For Melinta Therapeutics, Retail Calls It A ‘Wonderful Acquisition’ - Stocktwits
CorMedix Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
How did CRMD's Q4 earnings surprise impact investor confidence? - AInvest
It's A Story Of Risk Vs Reward With CorMedix Inc. (NASDAQ:CRMD) - simplywall.st
CorMedix (CRMD) Surpasses Q2 Earnings and Revenue Estimates - MSN
Cormedix Inc Reports Q2 2025 Earnings: $39.7M in Revenue, $0.29 EPS, and Acquisition of Melinta Therapeutics - AInvest
Applying big data sentiment scoring on CorMedix Inc.Free Consistent Income Focused Trade List - Newser
Press Release: Cormedix Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update - 富途牛牛
HC Wainwright Maintains Buy Rating on Cormedix, Adjusts Price Target to $17.00 - AInvest
Unraveling the Drop in CorMedix (CRMD.O): A Technical and Market Flow Deep Dive - AInvest
Cormedix Inc (CRMD) Q2 2025 Earnings Call Highlights: Strategic Acquisition and Positive ... By GuruFocus - Investing.com Canada
CorMedix signs agreement to acquire Melinta for $300m - Yahoo Finance
CorMedix: Q2 Earnings Snapshot - Greenwich Time
CorMedix Inc. Reports Strong Q2 2025 Results - TipRanks
Transcript : CorMedix Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Cormedix’s Strategic Growth Potential Boosted by Melinta Therapeutics Acquisition - TipRanks
CorMedix (CRMD.O) Suffers Sharp Intraday Drop: What’s the Story Behind? - AInvest
CRMD Faces Major Legal Battle - StocksToTrade
CorMedix Surpasses Expectations with Q2 Earnings Surge - AInvest
CorMedix Forecasts FY25 Pro Forma Revenue of $305M-$335M - AInvest
M&A News: CorMedix Stock (CRMD) Plunges 11% Despite $300M Melinta Deal - TipRanks
CorMedix buys Melinta Therapeutics for $300M - ROI-NJ
Cormedix Inc. shares fall 11.38% intraday after announcing $260M acquisition of Melinta Therapeutics, raising dilution and financing concerns. - AInvest
CorMedix To Acquire Melinta Therapeutics In $300 Mln Deal To Expand Infectious Disease Portfolio - Nasdaq
CorMedix to Buy Melinta Therapeutics for $300 Million - The Wall Street Journal
CorMedix to acquire Melinta Therapeutics for $300M - TipRanks
CorMedix Inc Azioni (CRMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.41%
0.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):